Cover Image
市場調查報告書

非何杰金氏淋巴瘤:主要18個國家的市場預測

Epiomic Epidemiology Series: Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027

出版商 Black Swan Analysis 商品編碼 436071
出版日期 內容資訊 英文 92 Pages
訂單完成後即時交付
價格
Back to Top
非何杰金氏淋巴瘤:主要18個國家的市場預測 Epiomic Epidemiology Series: Non-Hodgkin Lymphoma Forecast in 18 Major Markets 2017-2027
出版日期: 2017年02月01日 內容資訊: 英文 92 Pages
簡介

本報告提供全球主要18個國家的非何杰金氏淋巴瘤 (NHL)的發病情形相關分析,疾病概要和目前的患病人數,各子類型 (B細胞/T細胞) 及性別、各年代 (5歲區分)的詳細情況,各地區、各民族趨勢,風險要素,疾病診斷與預後,主要的症狀和併發症,未來趨勢預測 (今後10年份) 的資訊彙整,為您概述為以下內容。

目錄

  • 圖表一覽
  • 簡介
  • 疾病的原因
  • 風險要素與預防法
  • 疾病診斷方法
  • 各地區/各民族的差異
  • 疾病的預後和臨床過程
  • 疾病相關的主要的共生病症/特徵
  • 患者數的測量方法
  • 非何杰金氏淋巴瘤 (NHL)的最大患病人數
    • 主要的亞型
  • 非何杰金氏淋巴瘤患者的特徵
    • NHL患者的癌症病期
    • NHL患者的IPI (國際預後指標) 評分
    • 症狀的出現
  • B細胞淋巴瘤
    • 瀰漫性大型B細胞淋巴癌(DLBCL)
    • 濾泡型淋巴瘤
    • 週邊區域淋巴瘤
    • 被套細胞淋巴瘤
  • T細胞淋巴瘤
  • 文中的簡稱一覽
  • Black Swan Analysis的其他出版刊物
  • Black Swan Analysis的線上、病患人數的資料庫
  • 病患人數的服務
  • 線上價格資料/平台
  • 參考文獻
  • 附錄

分析觀察對象國家

  • 阿根廷、澳洲、巴西、加拿大、中國、法國、德國、印度、義大利、日本、墨西哥、俄羅斯、沙烏地阿拉伯、南非、西班牙、土耳其、英國、美國

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: NHLY0010117

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Non-Hodgkin Lymphoma in 18 Major Markets

Non-Hodgkin Lymphomas (NHL) are a diverse group of blood cancers that develop from lymphocytes (a type of white blood cell). As the name suggests, they include all lymphomas except Hodgkin's lymphoma. There are about 35 different subtypes of Non-Hodgkin Lymphomas. These are divided into two groups; aggressive (fast growing) and indolent (slow growing). NHL is also characterised by the cell type predominantly affected: either B cells or T cells.

This report provides the current incident population for Non-Hodgkin Lymphoma across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Brazil, Japan, India, China, Turkey, Mexico, Russia, Argentina, Australia, Saudi Arabia and South Africa) split by gender and 5-year age cohort. Along with the current incidence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Non-Hodgkin Lymphoma have been quantified and presented alongside the overall incidence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Non-Hodgkin Lymphoma include:

  • Painless, swollen lymph nodes in the neck, armpits or groin
  • Abdominal pain or swelling
  • Chest pain, coughing or trouble breathing
  • Fatigue
  • Fever; night sweats
  • Pruritis (severe itching of the skin)
  • Unexplained weight loss

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Able to quantify patient populations in global Non-Hodgkin Lymphoma market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the incidence of the subdivided types of Non-Hodgkin Lymphoma and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on Non-Hodgkin Lymphoma incident population.
  • Identify sub-populations within Non-Hodgkin Lymphoma which require treatment.
  • Gain an understanding of the specific markets that have the largest number of Non-Hodgkin Lymphoma patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors & Prevention
  • Diagnosis of the Disease
  • Variation by Geography/Ethnicity
  • Disease Prognosis & Clinical Course
  • Key comorbid conditions/Features associated with the disease
  • Methodology for quantification of patient numbers
  • Top-line incidence for Non-Hodgkin Lymphoma
  • Features of Non-Hodgkin Lymphoma patients
    • Staging of NHL patients
    • IPI score for NHL pat
    • Presence of Symptoms
  • B-cell lymphomas
    • Diffuse Large B-cell Lymphoma (DLBCL)
    • Follicular Lymphoma
    • Mantle cell Lymphoma
    • Burkitt's Lymphoma
  • T-Cell Lymphoma
  • Abbreviations used in the report
  • Other Black Swan Analysis Publications
  • Black Swan Analysis Online Patient-Based Databases
  • Patient-Based Offering
  • Online Pricing Data and Platforms
  • References
  • Appendix

List of Tables

  • Stages and modifiers of the Ann Arbour system
  • Risk assessment using the International Prognostic Index
  • Risk assessment using the FLIPI score
  • Incidence of Non-Hodgkin's Lymphoma, total (000s)
  • Incidence of Non-Hodgkin's Lymphoma, males (000s)
  • Incidence of Non-Hodgkin's Lymphoma, females (000s)
  • Predominant cell type (000s)
  • Ann Arbour Stage of Non-Hodgkin's Lymphoma (000s)
  • Ann Arbour Stage breakdown (stage I) (000s)
  • Ann Arbour Stage breakdown (stage II) (000s)
  • Ann Arbour Stage breakdown (stage III) (000s)
  • NHL patients by IPI Score, (000s)
  • NHL patients with systemic symptoms at diagnosis, (000s)
  • Incidence of B cell lymphoma, by main subtype, (000s)
  • Incidence of Diffuse large B-cell Lymphoma, (000s)
  • Diffuse large B cell lymphoma subtypes, (000s)
  • DLBCL by Ann Arbour Stage, (000s)
  • Incidence of Follicular Lymphoma (FL), (000s)
  • Follicular Lymphoma patients by FLIPI risk score, (000s)
  • FL patients by Ann Arbour Stage, (000s)
  • FL patients by predominant cell type, (000s)
  • Incidence of Mantle cell Lymphoma, total (000s)
  • Mantle Cell Lymphoma patients by Ann Arbour Stage, (000s)
  • Incidence of Burkitt's Lymphoma, (000s)
  • Burkitts Lymphoma by Ann Arbour Stage, (000s)
  • Incidence of T-cell Lymphoma by main subtype, (000s)
  • Abbreviations and Acronyms used in the report
  • USA Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • USA Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Canada Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Canada Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • France Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • France Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Germany Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Germany Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Italy Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Italy Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Spain Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Spain Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • UK Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • UK Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Brazil Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Brazil Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Japan Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Japan Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • India Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • India Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • China Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • China Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Turkey Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Turkey Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Australia Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Australia Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Mexico Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Mexico Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Argentina Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Argentina Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Russia Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Russia Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • Saudi Arabia Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • Saudi Arabia Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
  • South Africa Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, males (000s)
  • South Africa Incidence of Non-Hodgkin's Lymphoma by 5-yr age cohort, females (000s)
Back to Top